Wielka moc w małej cząsteczce : właściwości i zastosowania bisfosfonianów

• Autorzy: Kozicka Dominika , Socha Karolina , Szarek Jarosław , Kuźnik Anna

Identyfikatory

DOI

10.53584/wiadchem.2023.1.3

Warianty tytułu

EN

Great power in a small molecule : properties and applications of bisphosphonates

• Języki publikacji: PL

Abstrakty

EN

Bisphosphonates (BPs) are a group of compounds that are extensively studied around the world. Bisphosphonates are organophosphorus compounds characterized by the presence of the P-C-P skeleton. They are synthetic, thermally stable, and hydrolysis-resistant pyrophosphate analogs that occur naturally in living organisms. BPs have the ability to chelate metals such as magnesium and calcium which results in their high affinity to bone tissue. [1] The above factors determine their biological properties and the wide range of related applications. Bisphosphonates have an established position on the pharmaceutical market and have been used in medicine for many years, mainly as anti-resorptive drugs. They are considered the gold standard in the prevention and treatment of many different bone diseases, such as osteoporosis or Paget disease. [1] The therapeutic potential of bisphosphonates, however, is not limited to the treatment of bone diseases, as more and more reports about their other useful biological properties appear in the literature. [2] The usefulness of bisphosphonates in imaging diagnostics and drug delivery systems is also being explored. [3-5] The following article provides a short literature review on BPs, mainly their structure, properties, and mechanism of action, as well as their current and potential applications.

Słowa kluczowe

PL

bisfosfoniany; choroba kości; osteoporoza; obrazowanie kości; dostarczanie leków do kości

EN

bisphosphonates; bone diseases; osteoporosis; bone imaging; bone drug delivery

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2023
• Tom: [Z] 77, 1-2
• Strony: 55--73
• Opis fizyczny: Bibliogr. 57 poz., rys., wykr.

Twórcy

autor

Kozicka Dominika

• Katedra Chemii Organicznej, Bioorganicznej i Biotechnologii, Politechnika Śląska, B. Krzywoustego 4, 44-100 Gliwice
• Centrum Biotechnologii Politechniki Śląskiej, B. Krzywoustego 8, 44-100 Gliwice

• https://orcid.org/0000-0001-9418-1348

autor

Socha Karolina

• Katedra Chemii Organicznej, Bioorganicznej i Biotechnologii, Politechnika Śląska, B. Krzywoustego 4, 44-100 Gliwice

• https://orcid.org/0000-0002-2526-9837

autor

Szarek Jarosław

• Centralne Laboratorium Analityczne w Zabrzu, Piastowska 11, 41-800 Zabrze

• https://orcid.org/0000-0001-5029-2740

autor

Kuźnik Anna

• Katedra Chemii Organicznej, Bioorganicznej i Biotechnologii, Politechnika Śląska, B. Krzywoustego 4, 44-100 Gliwice
• Centrum Biotechnologii Politechniki Śląskiej, B. Krzywoustego 8, 44-100 Gliwice

• https://orcid.org/0000-0002-0801-7435

Bibliografia

• [1] R. G. G. Russell, Bone, 2011, 49, 2.
• [2] E. Chmielewska, P. Kafarski, Open Pharm. Sci. J., 2016, 3, 56.
• [3] E. Palma, J. D. G. Correia, M. P. C. Campello, I. Santos, Mol. BioSyst. 2011, 7, 2950.
• [4] K.B. Farrell, A. Karpeisky, D.H. Thammb, S. Zinnen, Bone Rep., 2018, 9, 47.
• [5] A. Kuźnik, A. Październiok-Holewa, P. Jewula, N. Kuźnik, Eur. J. Pharmacol., 2020, 866, 1.
• [6] H. A. Fleisch, R. G. G. Russell, S. Bisaz, R. C. Mühlbauer, D. A. Williams, Eur. J. Clin. Invest., 1970, 1, 12.
• [7] R. G. G. Russell, N. B. Watts, F. H. Ebetino, M. J. Rogers, Osteoporos. Int., 2008, 19, 733.
• [8] M. A. Lawson, Z. Xia, B. L. Barnett et al., J. Biomed. Mater. Res. B Appl. Biomater., 2010, 92, 149.
• [9] J. E. Dunford, K. Thompson, F. P. Coxon et al., J. Pharmacol. Exp. Ther., 2001, 296, 235.
• [10] M. J. Rogers, J. C. Crockett, F. P. Coxon, J. Mönkkönen, Bone, 2011, 49, 34.
• [11] H. Fleisch, „Bisphosphonates in bone disease. From the Laboratory to the Patient.”, Academic Press, Nowy Jork, 2000.
• [12] Narodowy Fundusz Zdrowia, NFZ o Zdrowiu. Osteoporoza, 2019, Warszawa.
• [13] D. M. Black, P. D. Delmas, R. Eastell, I. R. Reid, S. Boonen, J. A. Cauley, F. Cosman, P. Lakatos, P. C. Leung, Z. Man, C. Mautalen, P. Mesenbrink, H. Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T. F. Hue, D. Sellmeyer, E. F. Eriksen, S. R. Cummings, N. Engl. J. Med., 2007, 356, 1809–1822.
• [14] R. Czyżykowski, M. Krakowska, P. Potemski, Oncol. Clin. Pract., 2017, 13, 268–274.
• [15] S. Vallet, J.M. Filzmoser, M. Pecherstorfer, K. Podar, Pharmaceutics, 2018, 10, 1.
• [16] G.J. Morgan, F.E. Davies, W.M. Gregory, K. Cocks, S.E. Bell, A.J. Szubert, N. Navarro-Coy, M.T. Drayson, R.G. Owen, S. Feyler, A.J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. Rudin, G. Cook, G.H. Jackson, J.A. Child, Lancet, 2010, 376, 1989.
• [17] C.M. Shipman, M.J. Rogers, J.F. Apperley, R.G.G. Russell, P.I.B.J. Croucher, Haematol., 1997, 98, 665.
• [18] J. P. Polga, Clin. Nucl. Med. 1981, 6, 416.
• [19] R. D. Niederkohr, E. Chiu, J. A. Katzel, Clin. Nucl. Med. 2013, 38, 655.
• [20] F. De Geeter, K. Coenegrachts, Clin. Nucl. Med. 2007, 32, 32.
• [21] E. V. Giger, B. Castagner, J. C. Lerous, J. Control. Release, 2013, 167, 175.
• [22] A. Ezra, G. Golomb, Adv. Drug Deliv. Rev., 2000, 42, 175.
• [23] M. Drake, B. Clarke, S. Khosla, Mayo Clin Proc. 2008, 83, 1032.
• [24] P. Kosikowska, M. Bochno, K. Macegoniuk, G. Forlani, P. Kafarski, Ł. Berlicki, J. Enz. Inh. Med. Chem., 2016, 31, 931.
• [25] J. Agapkina, D. Yanvarev, A. Anisenko et al., Eur. J. Med. Chem., 2014, 73, 78.
• [26] C. M. Lacbay, J.Mancuso, Y. S. Lin, N. Bennett, M. Götte, Y. S. Tsantrizos, J. Med. Chem., 2014, 57, 7435.
• [27] S. Ghosh, J. M. W Chan, C. R. Lea et al. J. Med. Chem., 2004, 47, 175.
• [28] M. Gnant, P. Clézardin, Cancer Treat. Rev. 2012, 38, 407.
• [29] V. Stresing, F. Daubiné, I. Benzaid, H. Mönkkönen, P. Clézardin, Cancer Lett, 2007, 257, 16.
• [30] P. Fournier, S. Boissier, S. Filleur, J. Guglielmi, F. Cabon, M. Colombel, P. Clezardin, Cancer Res., 2002, 62, 6538.
• [31] J. Wood, K. Bonjean, S. Ruetz, A. Bellahcene, L. Devy, J.M. Foidart, V. Castronovo, J. R. Green, J. Pharmacol. Exp. Ther., 2002, 302, 1055.
• [32] A. Sasaki, B.F. Boyce, B. Story, K.R. Wright, M. Chapman, R. Boyce, G.R. Mundy, T. Yoneda, Cancer Res. 1995, 55, 3551.
• [33] T. Hiraga, P.J. Williams, G.R. Mundy, T. Yoneda, Cancer Res., 2001, 61, 4418.
• [34] E. Giraudo, M. Inoue, D.J. Hanahan, Clin. Invest., 2004, 114, 623.
• [35] J. Chang, W. Wang, H. Zhang, Y. Hu, Z. Yin, Z. Oncol. Lett., 2012, 4, 299.
• [36] T. Ohba, H.A. Cole, J.M.M. Cates, D.A. Slosky, H. Haro, T. Ando, H.S. Schwartz, J.G. Schoenecker, J. Bone Miner. Res., 2014, 29, 1431.
• [37] S. Wakchoure, M.A. Merrell, W. Aldrich, T. Millender-Swain, K.W. Harris, P. Triozzi, K.S. Selander, Clin. Cancer Res., 2006, 12, 2862.
• [38] Z. Ouyang, H. Li, Z. Zhai, J. Xu, C. R. Dass, A. Qin, K. Dai, K., Curr. Drug Targets, 2018, 19, 409.
• [39] M. Caraglia, M. Marra, S. Naviglio, G. Botti, R. Addeo, A. Abbruzzese, Expert Opin. Pharmacother., 2010, 11, 141.
• [40] D. Santini, M. Caraglia, B. Vincenzi, I. Holen, S. Scarpa, A. Budillon, Nat. Clin. Pract. Oncol., 2006, 3, 325.
• [41] H. L Neville-Webbe, A. Rostami-Hodjegan, C. A. Evans, R. EColeman, I. Holen, Int. J. Cancer, 2005, 113, 364.
• [42] A.Ullén, L. Lennartsson, U. Harmenberg, M. Hjelm-Eriksson, K. M. Kälkner, B. Lennernäs, S. Nilsson, Acta Oncol., 2005, 44, 644.
• [43] M. S. Benassi, A. Chiechi, F. Ponticelli, L. Pazzaglia, G. Gamberi, L. Zanella, M. C. Manara, P. Perego, S. Ferrari, P. Picci, Cancer Lett. 2007, 250, 194.
• [44] H. Hirabayashi, T. Takahashi, J. Fujisaki, T. Masunaga, S. Sato, J. Hiroi, Y. Tokunaga, S. Kimura, T. Hata, J. Control Release, 2001, 70, 183.
• [45] S. A. Gittens, G. Bansal, R. F. Zernicke, H. Uludag, Adv. Drug Deliv. Rev. 2005, 57, 1011.
• [46] P. P. Sedghizadeh, S. Sun, A. F. Junka,E. Richard,K. Sadrerafi, S. Mahabady,N. Bakhshalian, N. Tjokro, M. Bartoszewicz, M. Oleksy, P. Szymczyk, M. W. Lundy, J. D. Neighbors, R.G.G. Russell, C. E. McKenna, F. H. Ebetino J. Med. Chem., 2017, 60, 2326.
• [47] K. S. Tanaka, T. J. Houghton, T. Kang, E. Dietrich, D. Delorme, S. S. Ferreira, L. Caron, F. Viens, F. F. Arhin, I. Sarmiento, D. Lehoux, I. Fadhil, K. Laquerre, J. Liu, V. Ostiguy, H. Poirier, G. Moeck, T. R. Parr, A. R. Far, Bioorg. Med. Chem., 2008, 16, 9217.
• [48] A. El-Mabhouh, C. Angelov, A. McEwan, G. Jia, J. Mercer, Cancer Biother. Radio., 2004, 19, 627.
• [49] A. A. El-Mabhouh, P. N. Nation, J. T. Abele, T. Riauka, E. Postema, A. J. B.McEwan, J. R. Mercer, Oncol Res., 2011, 19, 287.
• [50] A. A. El-Mabhouh, C. A. Angelov, R. Cavell, J. R. Marcer, Nucl. Med. Biol. 2006, 33, 715.
• [51] E. Palma, J. D. Correia, M. P. Campello, I. Santos, Mol. BioSyst. 2011, 7, 2950.
• [52] L. E. Cole, T. Vargo-Gogola, R. K. Roeder, Adv. Drug Deliv. Rev., 2016, 99, 12.
• [53] V. Kubícek, J. Rudovský, J. Kotek, P. Hermann, L. Vander Elst, R.N. Muller, Z. I. Kolar, H. Th. Wolterbeek, J. A. Peters, I. Lukes, J. Am. Chem. Soc., 2005, 127, 16477.
• [54] Z. Zha, Z. Wu, S.R. Choi, K. Ploessl, M. Smith, D. Alexoff, L. Zhu, H.F. Kung, Mol Pharm., 2020, 17, 1674.
• [55] K. Ogawa, H. Kawashima, K. Shiba, K. Washiyama, M. Yoshimoto, Y. Kiyono, M. Ueda, H. Mori, H. Saji, Nucl. Med. Biol., 2009, 36, 129.
• [56] T. Vitha, V. Kubicek, P. Hermann, L. V. Elst, R. N. Muller, Z. I. Kolar, H. T. Wolterbeek, W. A. P. Breeman, I. Lukes, J. A. Peters, J. Med. Chem., 2008, 51, 677.
• [57] L. Sandiford, A. Phinikaridou, A. Protti et al., ACS Nano., 2013, 7, 500.

Uwagi

PL

Opracowanie rekordu ze środków MEiN, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2022-2023).